AlphaQuest LLC Has $48,000 Holdings in Enanta Pharmaceuticals, Inc. $ENTA

AlphaQuest LLC lessened its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 61.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,636 shares of the biotechnology company’s stock after selling 13,624 shares during the period. AlphaQuest LLC’s holdings in Enanta Pharmaceuticals were worth $48,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of ENTA. Stonepine Capital Management LLC bought a new position in Enanta Pharmaceuticals in the 4th quarter worth approximately $1,908,000. Millennium Management LLC raised its position in Enanta Pharmaceuticals by 22.7% in the 4th quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company’s stock worth $5,158,000 after purchasing an additional 165,692 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Enanta Pharmaceuticals by 52.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company’s stock worth $1,708,000 after purchasing an additional 102,646 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in Enanta Pharmaceuticals by 51.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company’s stock worth $1,668,000 after purchasing an additional 98,285 shares during the last quarter. Finally, Nuveen LLC bought a new position in Enanta Pharmaceuticals in the 1st quarter worth approximately $313,000. Institutional investors own 94.99% of the company’s stock.

Analysts Set New Price Targets

ENTA has been the subject of several research analyst reports. Westpark Capital initiated coverage on shares of Enanta Pharmaceuticals in a research report on Tuesday. They issued a “buy” rating and a $24.00 price objective for the company. JMP Securities boosted their price objective on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th. HC Wainwright began coverage on Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Buy” and an average target price of $22.25.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $8.89 on Friday. The firm’s fifty day moving average is $7.75 and its two-hundred day moving average is $6.78. The firm has a market cap of $190.07 million, a PE ratio of -2.06 and a beta of 0.84. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $13.37.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.40. The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.